A
Apollomics
Biotech & Life Sciences · Pleasanton, United States · Founded 2016
An innovative biopharmaceutical company committed to the discovery and development of oncology combination therapies MoreLess
Apollomics is a biotechnology company focused on the discovery and development of oncology combination therapies. Operating in both the U.S. and China, the company leverages partnerships with other biotechnology firms to enhance its capabilities. Founded in 2015, Apollomics has built a pipeline of ten drug candidates across 12 programs, with five candidates at the clinical stage. The pipeline is categorized into three groups based on mechanisms of action: tumor inhibitors, anti-cancer enhancers, and immuno-oncology drugs. Tumor inhibitors include small molecule inhibitors targeting uncontrolled growth signaling pathways, with a c-Met inhibitor as the core product. Anti-cancer enhancers are designed to boost the efficacy of other treatments and include antagonists developed as adjuncts to chemotherapy. Immuno-oncology drugs utilize the body's immune system to combat cancer, featuring mono-specific and bi-specific antibodies and a novel cancer vaccine. Apollomics aims to develop synergistic combination therapies to address unmet needs in cancer treatment.
Keywords: oncology, biotechnology, drug candidates, tumor inhibitors, anti-cancer enhancers, immuno-oncology, combination therapies, clinical stage, cancer treatment, partnerships
Company overview
Apollomics company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2016
- Headquarters
- Pleasanton, United States
- Employees
- 24
- Open positions
- None listed
- Dealroom signal
- 72.8
- Investment activity
- 1 companies · latest Jan 2019
- Capital deployed
- $59M
- Preferred round
- SERIES A
Valuation & funding
Apollomics funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO DEBTDebt | Mar 2026 | $2M | — | Undisclosed | ↗ |
| PRIVATE PLACEMENT VCOther financing | May 2024 | $6M | — | Undisclosed | ↗ |
| POST IPO EQUITYOther financing | Mar 2023 | $24M | — | Undisclosed | ↗ |
| SPAC IPOOther financing | Sep 2022 | $104M | $899M | Maxpro Capital Acquisition Corp | ↗ |
| SERIES COther financing | Nov 2020 | $124M | $497M | Ping An Capital · Ping An Group | ↗ |
| SERIES BOther financing | Jan 2019 | Pan-Lin Asset Management · CMB International Capital · OrbiMed · K2VC | — | ||
| SERIES AOther financing | Aug 2016 | OrbiMed | — | ||
| SPINOUTOther financing | Jan 2016 | University of Nottingham | — | ||
| SEEDOther financing | Jan 2016 | Undisclosed | — |
Financials
Revenue, earnings and profit over time
Reported history and available estimates. Estimated years are marked “E”; sparse fields are left blank rather than inferred.
| Year | Revenue | Growth | EBITDA | Margin |
|---|---|---|---|---|
| 2026 | $8.5M | 0% | −$8.8M | -103% |
| 2025 | $8.5M | — | −$8.8M | -103% |
| 2024 | $0 | — | −$40M | — |
| 2023 | $0 | — | −$174M | — |
| 2022 | $0 | — | −$239M | — |
| 2021 | $0 | — | −$91M | — |
| 2020 | $0 | — | −$73M | — |
Growth signals
Apollomics website traffic
Latest recorded traffic for Apollomics is 2.6K monthly website visits, up 0% over the last three months. Apollomics's team declined 11.1% over the past year.
Comparisons
Apollomics compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
| Company | Headquarters | Status | Employees | Total funding | Valuation |
|---|---|---|---|---|---|
 IGEM TherapeuticsImmuno-oncology IgE antibodies for treating solid tumors |
London, United Kingdom | Operational | 1 | $9.7M | $12M |
 GammaDelta TherapeuticsAllogeneic gamma-delta T-cell immunotherapies for cancer treatment |
London, United Kingdom | Acquired | |||
 Scenic BiotechGenetic modifier therapies for rare inherited diseases |
Amsterdam, Netherlands | Operational | |||
 SpyBiotechNovel vaccine platform using protein superglue technology |
Oxford, United Kingdom | Operational | |||
 Amphista TherapeuticsNext-generation therapeutics for targeted protein degradation |
Great Abington, United Kingdom | Operational | |||
 AvigenPreclinical selection platform for potent immune cells |
London, United Kingdom | Operational | |||
 BioCaptivaNovel liquid biopsy device for cancer diagnostics |
St Andrews, United Kingdom | Operational | |||
 Myricx BioNovel antibody-drug conjugate payloads for cancer treatment |
London, United Kingdom | Acquired |
Capital deployed
Apollomics investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Talent graph
Apollomics's talent
Source: Dealroom Talent Intelligence.
Investors
8 investors on Apollomics's cap table
Sourced from Dealroom's funding and investor records. Investor profile links are shown where available.
Global footprint
Where Apollomics has talent and traffic
team presence
In the news
Latest news about Apollomics
Recent press, funding announcements, and product moves mentioning Apollomics — open to read from the original sources.
Market sentiment
What the market is saying about Apollomics
An AI-synthesized read of the highest-engagement posts about Apollomics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Apollomics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.